Extracellular Vesicles Isolated from Plasma of Multiple Myeloma Patients Treated with Daratumumab Express CD38, PD-L1, and the Complement Inhibitory Proteins CD55 and CD59

Extracellular Vesicles Isolated from Plasma of Multiple Myeloma Patients Treated with Daratumumab Express CD38, PD-L1, and the Complement Inhibitory Proteins CD55 and CD59

Daratumumab (DARA) has improved the outcome of treatment of multiple myeloma (MM). DARA acts via complement-dependent and -independent mechanisms. Resistance to DARA may result from upregulation of the complement inhibitory proteins CD55 and CD59, downregulation of the DARA target CD38 on myeloma ce...

Full description

Bibliographic Details
Main Authors: Kieran Brennan, Katrine F. Iversen, Alfonso Blanco-Fernández, Thomas Lund, Torben Plesner, Margaret M. Mc Gee
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Cells
Subjects:
daratumumab
extracellular vesicles
plasma
bone marrow
multiple myeloma
complement
Online Access:https://www.mdpi.com/2073-4409/11/21/3365

Similar Items

Similar Items